Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Chemotherapy in Malignant Pleural Mesothelioma (MAPS)
NCT00651456Phase 3Completed
- Sponsor
- IFCT
- Start
- Feb 2008
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in malignant pleural mesothelioma (MPM) (2 arms), sponsored by IFCT. Primary endpoints: Overall Survival and Disease Control Rate at 6 months. Started Feb 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00651456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651456.